Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM5C | P41229 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 7/20 | 1.00 |
| ▸ | KDM2A | Q9Y2K7 | 6/20 | 1.00 |
| ▸ | KDM3A | Q9Y4C1 | 6/20 | 1.00 |
| ▸ | KDM6B | O15054 | 5/20 | 1.00 |
| ▸ | JMJD6 | Q6NYC1 | 2/20 | 0.66 |
| ▸ | KDM4A | O75164 | 6/20 | 0.60 |
| ▸ | KDM5B | Q9UGL1 | 7/20 | 0.59 |
| ▸ | P4HA1 | P13674 | 1/20 | 0.58 |
| ▸ | KDM4B | O94953 | 3/20 | 0.55 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | KDM5A | P29375 | 3/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | TET3 | O43151 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29670732 | 1.00 | KDM5C (1.00) | KDM5CKDM4EKDM4CKDM2AKDM3A | |
| SCHEMBL10052344 | 0.94 | KDM5C (0.88) | KDM5CKDM4EKDM4CKDM2AKDM3A | |
| SCHEMBL70279 | 0.93 | KDM4E (0.86) | KDM5CKDM4EKDM4CKDM2AKDM3A | |
| SCHEMBL29894587 | 0.93 | KDM4E (0.86) | KDM5CKDM4EKDM4CKDM2AKDM3A | |
| SCHEMBL6514670 | 0.91 | KDM4E (0.83) | KDM5CKDM4EKDM4CKDM2AKDM3A | |
| Hydrochloric Acid SCHEMBL6504834 | 0.91 | KDM4E (0.83) | KDM5CKDM4EKDM4CKDM2AKDM3A | |
| SCHEMBL30774379 | 0.86 | KDM4E (0.76) | KDM5CKDM4EKDM4CKDM2AKDM3A | |
| SCHEMBL714108 | 0.86 | KDM4E (0.76) | KDM5CKDM4EKDM4CKDM2AKDM3A | |
| SCHEMBL19229659 | 0.86 | KDM4E (0.76) | KDM5CKDM4EKDM4CKDM2AKDM3A | |
| SCHEMBL70700 | 0.85 | KDM4C (0.78) | KDM5CKDM4EKDM4CKDM2AKDM3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114874127-A | Preparation method of difluorocarbonylation indolone compound | 中国药科大学 | 2022-08-09 | — | — | CN | claimed |
| CN-105906555-A | Preparation method of 2, 2'-bipyridine-4, 4'-diacrylic acid | 河南省商业科学研究所有限责任公司 | 2016-08-31 | — | — | CN | claimed |
| CN-115677569-B | Synthesis method of pyridines and substituted benzenes based on reduction coupling reaction of iron-catalyzed aryl halide and alkyl halide | 重庆大学 | 2024-05-28 | — | — | CN | disclosed |
| CN-111378144-A | Force-induced response supramolecular polymer | 翁秋梅 | 2020-07-07 | — | — | CN | disclosed |
| US-10316050-B2 | PT (IV) complexes containing 4,4′-disubstituted-2,2′-bipyridyl and their use in cancer therapy | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2019-06-11 | — | — | US | disclosed |
| CN-109438339-A | RBP2 enzyme inhibitor small molecule compound WXSA-072A and preparation method thereof and anti-gastric cancer application | 山东大学 | 2019-03-08 | — | — | CN | disclosed |
| EP-2595613-B1 | COMPOUNDS FOR USE IN A METHOD OF PREVENTING OR TREATING VIRAL INFECTION | US HEALTH (US) | 2019-01-09 | — | — | EP | disclosed |
| CN-105906555-B | The method that one kind prepares 2,2 '-bipyridyl -4,4 '-diacrylate | 河南省商业科学研究所有限责任公司 | 2018-04-24 | — | — | CN | disclosed |
| US-20170233423-A1 | PT (IV) Complexes Containing 4,4'-Disubstituted-2,2'-Bipyridyl and Their Use in Cancer Therapy | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS | 2017-08-17 | — | — | US | disclosed |
| CN-105906555-A | Preparation method of 2, 2'-bipyridine-4, 4'-diacrylic acid | 河南省商业科学研究所有限责任公司 | 2016-08-31 | — | — | CN | disclosed |
| CN-105906555-A | Preparation method of 2, 2'-bipyridine-4, 4'-diacrylic acid | 河南省商业科学研究所有限责任公司 | 2016-08-31 | — | — | CN | disclosed |
| WO-2016025742-A1 | PT(IV) COMPLEXES CONTAINING 4,4'-DISUBSTITUTED-2,2'-BIPYRIDYL AND THEIR USE IN CANCER THERAPY | THE BOARD OF REGENTS OF THE NEVADA SYSTEM OF HIGHER EDUCATION ON BEHALF OF THE UNIVERSITY OF NEVADA, LAS VEGAS (US) | 2016-02-18 | — | — | WO | disclosed |
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871789-B2 | Method of preventing or treating viral infection | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES (US) | 2013-05-16 | — | — | US | disclosed |
| WO-2012012627-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2010043866-A2 | HISTONE LYSINE DEMETHYLASE INHIBITORS | ISIS INNOVATION LIMITED (GB) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233423-A1 | PT (IV) Complexes Containing 4,4'-Disubstituted-2,2'-Bipyridyl and Their Use in Cancer Therapy | PARP2, ERBB2, TOP2A | KDM5C 2747/4885KDM4E 1686/4885KDM4C 1297/4885 |
| US-20130123344-A1 | METHOD OF PREVENTING OR TREATING VIRAL INFECTION | KDM1B, KDM1A, KDM2A | KDM5C 16/4885KDM4E 21/4885KDM4C 20/4885 |
| US-10316050-B2 | PT (IV) complexes containing 4,4′-disubstituted-2,2′-bipyridyl and their use in cancer therapy | TOP2A, ERBB2, PARP2 | KDM5C 2659/4885KDM4E 1661/4885KDM4C 1295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.